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Abstract
Psychotic disorders are among the most complex medical conditions. Longitudinal cohort studies may offer further insight
into determinants of functional outcome after a psychotic episode. This paper describes the Psychosis Recent Onset in
GRoningen Survey (PROGR-S) that currently contains data on 1076 early-episode patients with psychosis, including
symptoms, personality, cognition, life events and other outcome determinants. Our goal in this report is to give an overview
of PROGR-S, as a point of reference for future publications on the effect of cognition, personality and psychosocial
functioning on outcomes. PROGR-S contains an extensive, diagnostic battery including anamnesis, biography, socio-
demographic characteristics, clinical status, drug use, neuropsychological assessment, personality questionnaires, and
physical status tests. Extensive follow-up data is available on psychopathology, physical condition, medication use, and care
consumption. Sample characteristics were determined and related to existing literature. PROGR-S (period 1997–2009,
n = 718) included the majority of the expected referrals in the catchment area. The average age was 27 (SD= 8.6) and two-
thirds were male. The average IQ was lower than that in the healthy control group. The majority had been diagnosed with a
psychotic spectrum disorder. A substantial number of the patients had depressive symptoms (479/718, 78%) and current
cannabis or alcohol use (465/718, 75%). The level of community functioning was moderate, i.e. most patients were not in a
relationship and were unemployed. The PROGR-S database contains a valuable cohort to study a range of aspects related to
symptomatic and functional outcomes of recent onset psychosis, which may play a role in the treatment of this complex
and disabling disorder. Results reported here show interesting starting points for future research. Thus, we aim to
investigate long-term outcomes on the basis of cognition, personality, negative symptoms and physical health. Ultimately,
we hope that this paper will contribute improving the health of patients with psychotic disorders.
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Introduction
Psychotic disorders are among the most disabling and expensive
medical conditions with a lifetime prevalence of almost 3% [1].
Diagnostic assessment is complex due to the multifactorial etiology
and heterogeneous course of such disorders [2]. Whereas some
patients may recover, others experience an unfavorable course of
illness [3,4]. The reasons for this heterogeneous course are still
unclear, but intervention in the early stages of the illness may be
an important determinant for functional recovery [5–7]. Longi-
tudinal cohort studies may offer insight into determinants of
functional outcome after a psychotic episode. The goal of this
paper is to give an overview of such determinants using the
Psychosis Recent Onset in GRoningen Survey (PROGR-S) for the
first time. This paper should also serve as a point of reference for
future publications.
Besides genetic predisposition, life events may determine
whether an individual develops psychosis. First episode patients
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have a higher incidence of traumatic life events [6], which are
predictive for the development of psychosis [8]. Personality
characteristics and coping skills, e.g. for stress management also
influence the risk of developing psychosis [9–11]. Social relation-
ships may help to reduce stress and inhibit the conceptualization of
delusional ideas [12], but individuals with psychosis often
experience problems maintaining peer relationships [13]. A
satisfying living situation and occupation also reduce the risk of
developing a psychosis [12].
Lower educational achievements and IQ levels have also been
associated with increased risk for psychosis [6,13] and poor social
outcomes [14,15]. These factors may be indicative of cognitive
impairments, which are key symptoms of psychotic disorders
[16,17]. However, a substantial variation in impairment of
cognitive functioning is observed across psychotic patients [18–
20] and 25% of patients exhibit cognitive performance within
normal limits [21,22]. Thus, cognition could be a predictor of
outcome, along with positive and negative symptoms [23].
Treatment of psychosis should start as early as possible, since a
longer duration of untreated psychosis (DUP) may predict poorer
outcomes [24]. Antipsychotics are a first and important step in
treatment, but functional recovery is often poor despite initial
symptom reduction [25,26]. On the other hand, continuation of
antipsychotic treatment may prevent relapses [27], at the cost of
serious side effects. Owing to these complex considerations, the
optimal treatment strategy for an individual patient is difficult to
determine on the basis of current knowledge.
Psychotic patients often have an unhealthy lifestyle (smoking,
sedentary, unhealthy food intake) [28,29]. Combined with
antipsychotic treatment, this lifestyle is a risk factor for metabolic
syndrome, obesity, movement disorders, liver and kidney dysfunc-
tion, diabetes and cardiovascular problems [30–33]. Moreover,
psychotic patients often use substances that may exacerbate
psychosis, such as alcohol, cannabis, amphetamines, hallucino-
gens, and sedatives [34]. Routine screening for metabolic
problems may help to reduce the risk of comorbid physical
disorders [30,35–37].
Other cohort studies have already focused on first-episode
samples, but often on the basis of a limited diagnostic range, poor
definition of the catchment area, unstructured information on
environmental and contextual factors, lack of information on
interventions and neuropsychological function, small sample sizes,
no control group, and limited follow-up data [6,7,24,38].
This paper provides an overview of the research setting of the
Psychosis Recent Onset in GRoningen Survey (PROGR-S) from
the Northern Netherlands. PROGR-S is designed to collect data
on symptoms, cognition, personality, life events, drug abuse,
psychological and physical status, and other determinants that
may influence functional outcome in recent-onset psychotic
patients [5–7,38]. To date, PROGR-S contains 1076 participants
with a recent onset psychosis, and growing, and a matched healthy
control group. PROGR-S can be linked to databases with detailed
follow-up information on outcome, including a database with
annual measurements of physical and psychological health status,
social and occupational functioning and quality of life (For an
overview of this database: Bartels et al., in prep.), and two
databases on daily care consumption and daily medication use.
Methods
Study sample
The diagnostic protocol for PROGR-S was established in 1997
for all inhabitants (550,000) in the Groningen province in the
Netherlands who were referred to a psychiatric institution with a
suspected recent onset psychotic episode (,2 years) or evaluated
for a recurrent psychotic episode not diagnosed as such before.
There was no exclusion based on age, diagnoses, substance abuse,
or ethnicity. The database currently contains 1076 patients. A
sample of 718 validated cases was analyzed for the current report
(1997–2009). Between 1997 and 2009, an average of 62 patients
were included each year in the PROGR-S database. Certain
patients from this period were excluded after referral for the
following reasons: no consent for scientific research (n = 5), no
show/stopped (n = 13), non-native language (n = 5), second
opinion or previously included (n= 5), moved or referred (n= 5),
unknown reason (n = 4).
All study procedures were carried out in accordance with the
declaration of Helsinki. All data was primarily collected for clinical
purposes. Participants gave oral and written informed consent
after procedures had been fully explained on the use of the data in
our research database, as approved by the Institutional Review
Board (IRB). All procedures were in accordance with local and
international rules as confirmed by the local ethical committee of
the University Medical Center of Groningen. The medical ethical
committee of the University Medical Center Groningen declared
that their approval was not required, as data were collected for
diagnostic purposes, no interventions outside standard care were
performed, and data were anonymized for research purposes.
Clinical interviews took place at the clinic at the time of
admission. Psychological testing and interviews on clinical
background information were carried out after two months,
because the first florid psychotic symptoms have often remitted by
that time, and would likely interact with test results. All procedures
were conducted in Dutch in accordance with standardized
protocols. For neuropsychological assessments and personality
questionnaires, patients had to be native Dutch speakers. The
results of these tests are standardized to the Dutch population. The
PROGR-S-protocol takes 7–9 hours to complete, divided over
two sessions.
Measurements
PROGR-S serves as a baseline measurement after a first
psychosis. For a large number of patients, a yearly follow-up
measurement is also avaiable (Pharmacotherapy Outcome and
Monitoring Survey; PHAMOUS; Bartels et al., in prep.).
Moreover, there is a daily registration of care consumption by
the Psychiatric Case Registry Northern Netherlands (PCRNN).
For an overview of all measures, see File S1. The PROGR-S-
protocol included the following assessments:
Anamnesis (medical history) and biography: obtained from the
patient and, if possible, together with close relations (mostly
parents) for hetero-anamnesis and information on childhood
development. Anamnesis included nature, severity, and conse-
quences of symptoms for daily functioning, along with the use of
medication, recreational drugs, and family anamnesis (history of
illness in family). The biography focused on signs of an early
developmental disorder, childhood and current psychological
traumas (such as abuse, neglect, and personal loss), and the
highest level of social and intellectual functioning reached,
including living situation and occupation.
Clinical and diagnostic data: The Positive and Negative
Syndrome Scale (PANSS): a semi-structured interview on symp-
tom severity of psychotic disorders including three subscales,
Positive symptoms, Negative Symptoms and General psychopa-
thology [39]; Montgomery-Asberg Depression Rating Scale
(MADRS ): a semi-structured interview on the severity of
depressive symptoms that may be more sensitive to treatment
effects than other depression interviews [40,41]; Schedules for
The Psychosis Recent Onset GRoningen Survey (PROGR-S)
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Clinical Assessment in Neuropsychiatry (SCAN ): a comprehensive
psychiatric diagnostic interview (Diagnostic and Statistical Manual
of Mental Disorders; DSM-IV) and severity on the basis of an
algorithm [42]; Global Assessment of Functioning (GAF): a DSM-
IV rating by the clinician indicating the level of social,
occupational, and psychological functioning of the individual
[43]. The Camberwell Assessment of Needs (CAN) measures
whether the clinical and social needs of people with severe mental
illnesses are being met [44].
Functioning measurements: Groningen Social Disabilities
Schedule (GSDS): a schematic interview on disabilities in social
functioning in the domains of self-care, household activities and
relations with close family, extended family and partner, societal
integration, relationships with friends, work, and daily activities
[45]; Psychological assessment including most neurocognitive
domains of the Measurement and Treatment Research to Improve
Cognition in Schizophrenia) Consensus Cognitive Battery (MA-
TRICS)-Consensus [46], except social cognition: the Stroop Test
[47,48], Trail Making Test [49], California Verbal Learning Test,
Dutch edition [50], Continuous Performance Test [51], Finger
Tapping Test [52], and the Digit Symbol Substitution, Block
Design, Arithmetic and Information subtest of the Wechsler Adult
Intelligence Scale (WAIS) III [53], administered in a fixed order
within approximately two hours.
Personality measures: Neuroticism-Extroversion-Openness -
Five-Factor Inventory (NEO-FFI): a self-report personality ques-
tionnaire that includes five important domains of personality,
namely Neuroticism, Extraversion, Openness, Agreeableness, and
Conscientiousness [54] -Dutch version [55]; Utrecht Coping List
(UCL): a self-report questionnaire measuring a range of coping
strategies, including Problem solving, Distraction, Avoidance,
Social support, Passive coping, Emotional expression, and
Comforting [56].
Physical health status: Physical examination includes blood
pressure, heart rate, height and weight. If necessary, additional
tests can be performed; Laboratory tests include testing for general
health conditions, anemia, liver function, signs of diabetes, risk
factors for heart and vascular disease, kidney function, pituitary
function, and syphilis.
Training and instruction of test psychologists for the neurocog-
nitive battery were conducted on site in order to ensure uniform
testing. Psychiatrists were trained by the Groningen World Health
Organization (WHO) Training Center to administer the SCAN
diagnostic interview (see below). Training of the research nurses
for PANSS and GSDS (see below) was provided at investigator
meetings, supplemented by written training materials. Training for
the PANSS and GSDS included rating a videotaped interview,
followed by discussion and review of ratings in accordance with
strict guidelines (e.g. PANSS score should not deviate more than
one point per item). Booster meetings were organized annually, to
maintain inter-rater reliability.
Control sample
A healthy control sample (n = 70) was selected based on random
sampling from the community through the local municipal
administration. Selected controls (n = 1000) received an informa-
tion letter informing them about the study and inviting them to
participate. In total, 93 controls responded to the invitation and 70
were eligible for inclusion in the study. Five individuals had to be
excluded and 18 declined to participate or were no shows.
Controls were matched with patients on age, gender and highest
educational level. A male/female ratio similar to the patient
sample was included, and because onset of psychosis generally
occurs early in life, we selected healthy subjects between 18 and 50
years old. Exclusion criteria for controls included a psychiatric or
neurological history or a first-degree family member with a
psychiatric diagnosis (defined as absence of any lifetime psychiatric
symptoms assessed with the screening questions of the SCAN-
interview) [42]. Subjects were excluded if they had an excessive
alcohol intake (21 units per week for males and 15 for females;
according to Dutch government guidelines), more than one unit of
cannabis per week or any hard drugs. Participants were instructed
to abstain from cannabis and alcohol for 24 hours prior to testing.
The research protocol for controls included the cognitive test-
battery, NEO-FFI, UCL, and demographic data including age,
gender, educational achievements and occupation.
Research data management
Certified medical staff performed data collection. Patient
information for clinical purposes was stored in the local mental
health care information system and in paper medical records.
Research assistants entered data for the research database from
the medical records using the Statistical Package for the Social
Sciences (SPSS 20; IBM Inc. New York, USA). Personal data and
research data could not be linked directly. Researchers using the
database received an anonymized version. The PROGR-S
database is too comprehensive and valuable to be made publicly
available without any restrictions. In accordance with the PLOS
ONE data sharing policy, data from the PROGR-S cohort is
available by contacting Edith Liemburg (e.j.liemburg@umcg.nl).
Persons requesting data should fill in a short data-request form
indicating their research question and aims, desired variables, and
a short description of the analysis plan. After approval by the
PROGR-S steering committee, a custom-made database with the
requested data will be provided.
For an overview of the sample, socio-demographic and clinical
data are presented in this paper. Socio-demographic data are
shown for patients and healthy controls: education level (elemen-
tary school (1) up to university (8) [57], ethnicity (native or not),
occupation, living situation and IQ (based on WAIS III [53]).
Clinical data on patients is also included: DSM-IV diagnosis
(grouped according to Bromet et al. [58], GAF score, PANSS
score, MADRs score and categorization of severity of depression
according to Hermann et al. [59], number of psychotic episodes,
duration of untreated psychosis (DUP), lifetime drug/alcohol use,
and use of antipsychotics (haloperidol equivalents according to
Andreasen et al. [60].
Due to non-normal distribution of the data, a Mann Whitney U
test had to be used to compare patients with healthy controls on
age, IQ and education level, and a Chi-square test for
independence to test for differences in gender distribution. Other
characteristics, such as occupation, were only compared visually
between both groups.
Results
The PROGR-S database currently includes 1076 patients. In
this paper, we included a validated set of 718 patients (1997–
2009). Table 1 gives an overview of the socio-demographic
characteristics of both patients and healthy controls (n = 70). The
average age is 27 years (SD=8.6) and 73% of the sample is male.
Patients and healthy controls were of a similar age (Z=0.88,
p=0.38). Although onset of psychosis is often later in females than
The Psychosis Recent Onset GRoningen Survey (PROGR-S)
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males, the age distribution for males and females was similar in
patients and matched healthy controls, except that female controls
had a non-significant larger age range (Z=1.0, p=0.32) (25%,
50%, 75%; male patients: 21, 25, 31 years; male controls: 22, 25,
29; female patients: 22, 26, 33; female controls: 21, 29, 44).
Despite specific selection of males at later stages of the study, the
gender ratio was significantly different in each group (x2 = 8.7,
p=0.003). Patients also had a lower level of the highest level of
education reached (Z=8.0, p,0.005) and a lower IQ (Z=7.7, p,
0.0005). Only one third of patients had a paid job and almost half
were unemployed, whereas only one person in the control group
was unemployed. Moreover, 50% of the control sample were
students versus only 16% of patients.
Table 2 shows the clinical characteristics of the patient sample.
As patients could be referred for any type of disorder that may
include psychotic symptoms, some patients had a primary
diagnosis outside the psychotic spectrum. Moreover, due to the
recent onset of psychosis, a definitive diagnosis could often not be
established at that point, resulting in a high incidence of
differential and comorbid diagnoses. The other primary diagnoses
in Table 2 included the following: cannabis abuse/dependence
(n = 8), other substance abuse/dependence (n = 3), autistic/devel-
opmental problems (n = 5), somatoform disorder (n = 2), Tour-
ette’s syndrome (n= 1), dissociative disorder (n = 2), identity
problems (n= 2), and others (n = 5) = . It is worth noting that
these patients had a diagnosis on the psychotic spectrum as
differential or comorbid diagnosis. The average level of function-
ing according to the GAF was moderate (mean= 54.4, SD=13.8).
Although all patients were treated for a first episode of psychosis,
14.4% reported similar psychotic symptoms in the past, and were
therefore reported here as second or third episode psychosis. The
DUP was shorter than three months for 36% (for the known cases;
175 out of 479). The average severity of symptoms during the
PANSS-interview was mild to moderate, i.e. an average PANSS
score per item of 2–3 (mild-moderate). A substantial number of
individuals reported depressive symptoms and current substance
use, mainly cannabis or alcohol. 80% of the patients were already
receiving antipsychotic treatment at the time of inclusion in
PROGR-S, with an average dosage of 6 mg (SD=3.8) of
haloperidol equivalents.
Discussion
This article presents the objectives, recruitment strategies,
assessment methods, and sample characteristics of the PROGR-
S database. Many factors influence outcomes for patients with
psychosis [58]. PROGR-S will enable us to study these factors in
Table 1. Overview of demographical and clinical characteristics of the patients and controls in PROGR-S, the last column give the
p-value of the comparison between both groups.
Patients Controls p-value
mean (SD; range)/number (%) mean (SD; range)/number (%)
Age 27.7 (8.6; 16–69) 28.8 (9.3; 18–49) 0.38
Gender Male 525 (73.0) 39 (55.7) 0.003
Female 193 (27.0) 31 (44.3)
Education Elementary school 4 (0.6) 1 (1.4) ,0.0005
highest level Secondary school 122 (16.9) 1 (1.4)
reached1 High school 58 (8.1) 3 (4.3)
Vocational education 245 (34.1) 4 (5.7)
University 259 (36.1) 61 (87.2)
Other 30 (4.2) 0
IQ2 93.3 (14.3; 54–138) 110.7 (14.7; 75–140) ,0.0005
Ethnicity Native 594 (82.7) 97.1
Non-native 124 (17.3) 2.9
Occupation Unemployed 309 (43.0) 1 (1.4)
Paid job 219 (30.5) 37 (52.9)
Voluntary job 39 (5.4)
Student 114 (15.9) 31 (44.3)
Other 7 (1.0) 0
Living situation Married 35 (4.9) 9 (12.9)
Living alone 353 (49.2) 14 (20.0)
Living with parents 242 (33.7) 2 (2.9)
Partner (not married) 50 (7.0) 26 (37.1)
Mental health institute 22 (3.1) 0
Other 16 (2.2) 0
1According to Verhage, 1984 [57].
2Based on the WAIS III [53].
doi:10.1371/journal.pone.0113521.t001
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Table 2. Clinical characteristics of participants in PROGR-S.
mean SD range %
Diagnosis1 No diagnosis 0.7
Schizophrenia 42.3
Substance induced psychosis 4.2





Affective disorders, other 6.0
Other diagnoses 5.1
GAF2 54.4 13.8 16–99









PANSS Positive subscale 12.6 4.8 7–32
PANSS Negative subscale 14.3 6.0 7–41
PANSS General subscale 29.7 8.1 16–64









Present state (3 months) Cannabis 29.5
Alcohol 12.7
Other substances 0.7
Use of antipsychotics (dose & % using) Medication naive 19.1
Use of common antipsychotics (dose & % using) Risperidone 3.2 1.5 1–10 23.7
Olanzapine 12.3 5.6 2–30 28.0
Quetiapine 463.7 244.9 50–1000 7.9
Clozapine 360.4 135.3 127–750 5.2
Aripiprazole 13.1 6.0 7.5–30 3.6
Other oral antipsychotics 7.9
Haloperidol equivalents4 6.3 3.8
1According to SCAN-interview (Giel and Nienhuis, 1996) [42].
21 = severe dysfunction, 100 = optimal functioning.
3Categorized according to Herrmann et al. (1998) [59].
4According to Andreassen et al., 2010 [60].
doi:10.1371/journal.pone.0113521.t002
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more detail. The descriptive overview of the present paper [61]
sets the stage for future PROGR-S-based reports.
Between 1997 and 2009, an average of 62 patients were
included every year in the PROGR-S database. The province of
Groningen has a population of 550,000. On the basis of an
incidence of psychosis of between 10 and 20 per 100 000 persons
in the Netherlands [62], we estimate that between 55 and 110
persons within the province will develop psychosis every year. This
indicates that PROGR-S has a relatively good catchment and
therefore a representative geographic cohort. In the following
paragraphs, relevant sample characteristics are discussed and
comparisons are drawn with other studies.
The socio-demographic characteristics of our sample fit the
general picture for patients with a psychotic illness [24,38,63–65].
Most patients in the sample were aged between 20 and 30 years,
and the male - female ratio was 2: 1 [66]. Moreover, most patients
were unemployed and lived alone or with their parents. Healthy
peers often had a job and higher educational achievements than
patients. This may indicate that patients with a recent onset
psychosis have less beneficial living conditions than their peers
without a disorder. Social engagement and personality are
important indicators for outcome in psychosis [67–69]. At present,
research is underway on how personality and social participation
influence outcomes for psychotic patients. Unfortunately, infor-
mation on the living situation of healthy controls was not recorded.
However, our database will be linked to socio-demographic data
(including living situation) collected by the Dutch government,
which is expected to provide interesting opportunities for future
research.
Patients had an average IQ of 93, whereas the average IQ of the
control group was 111. Notably, a relatively large proportion of
the patient group had university level education, which can be
explained by the fact that Groningen is a university town. It has
been shown that neurocognitive deficits already existed before the
first episode of psychosis, and that cognitive therapy may help to
improve cognition, in contrast with medication [70,71]. One of
our goals will be to investigate whether first episode cognitive
function predicts functional outcome later on.
Approximately 36% of the patients experienced a DUP shorter
than three months and there was a wide variety in length. These
findings are similar to those of other studies [24,63,65].
Unfortunately, a long DUP may result in an unfavorable outcome
for a recent onset psychosis [72]. The wide variety in DUP we
observed may be an interesting starting point to study the effect of
treatment in early versus late stages of psychosis [73]. The GAF
score was around 55 (optimal functioning = 100), which seems to
be in line with other first episode psychosis studies [24,63,64].
Combined with the mild to moderate PANSS scores [38], these
results indicate that patients were not severely ill at the time the
diagnostic interview was administered. This may be explained by
the use of antipsychotics at the time of assessment. The majority of
the patients were already taking antipsychotic medication. The
average dose of 6 mg haloperidol equivalents is relatively high
according to current indications [74]. However when data
collection began, higher doses were common practice. Dosages
declined over time in our sample, with an average of 6.4 in the first
year and 5.6 in the last year. Some of the patients used multiple
antipsychotics or relatively high doses of first-generation antipsy-
chotics. Moreover, the haloperidol equivalents calculated [60] may
be relatively high, e.g. for risperidone. It is worth noting that
although minimal intervention with medication is often advised,
recent studies show that discontinuation lead to a high risk of
symptom reoccurrence [75]. Furthermore, a quarter of patients
show persistent symptoms after treatment[76], and treatment
response may be predicted based on baseline factors [77]. The
follow-up databases contains detailed information on medication
prescriptions and related health status of the patients, because
improvement of treatment and physical health is our main
research goal.
Three quarters of the patients in the PROGR-S database
reported past or current use of cannabis or alcohol. This fits with
earlier findings in other studies on psychotic patients [63,78]. It
has been shown that individuals with a psychotic disorder who use
cannabis are more likely to develop psychotic symptoms than
healthy controls [79,80] and that cannabis may cause long-term
cognitive impairments [81]. Scientific knowledge on the effect of
alcohol abuse on psychosis is limited. We hope that our database
will provide important information on the effect of cannabis,
alcohol, and other drugs on the clinical course after a psychosis.
According to the MADRS, a high incidence of mild to
moderate depression was present in the PROGR-S patient sample
(n = 479/78%), which fits with earlier reported incidences of
depression in psychotic patients [63,82], including in our follow-up
sample [83]. Given the major burden of depression on top of other
symptoms of psychosis, this should be an important focus for
future research.
The primary goal of PROGR-S is to collect data for diagnostic
assessment; therefore the database may not be entirely suited for
scientific purposes. However, the large naturalistic sample,
covering more than 75% of patients with psychosis in the province
of Groningen may outweigh this, as generalization to the
population is desirable. Moreover, socio-demographic matching
of our healthy control sample was limited, despite our efforts. We
will extend the control group to achieve better matching.
Opportunities to link the information to other existing databases
add to the value of PROGR-S. In this way, costs savings can be
achieved as outcomes can be derived from existing initiatives.
In conclusion, the PROGR-S database is a valuable geographic
cohort that can be used to study various aspects that may play a
role in the treatment of psychosis. In future studies, we will
examine hypotheses on the effect of neurocognitive capacities,
psychosocial functioning, personality traits and coping styles on
functional outcome. Ultimately, we hope to gain more insight into
outcome of psychotic disorders that will contribute to health
improvements in patients with psychotic disorders.
Supporting Information
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